Similar articles

• Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.

  Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM. Clifford DB, et al. Ann Intern Med. 2005 Nov 15;143(10):714-21. doi: 10.7326/0003-4819-143-10-200511150-00008. Ann Intern Med. 2005. PMID: 16287792 Clinical Trial.
• Reply to Gonzalez and Everall: Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.

  Colebunders R, Verdonck K. Colebunders R, et al. AIDS. 1999 May 7;13(7):869. doi: 10.1097/00002030-199905070-00024. AIDS. 1999. PMID: 10357394 No abstract available.
• Efavirenz and retinal toxicity.

  Lewis A, Mitchell S. Lewis A, et al. Eye (Lond). 2002 Jan;16(1):107. doi: 10.1038/sj.eye.6700038. Eye (Lond). 2002. PMID: 11913879 No abstract available.
• NNRTI hepatotoxicity: efavirenz versus nevirapine.

  Pulido F, Torralba M. Pulido F, et al. J HIV Ther. 2002 Nov;7 Suppl 2:S3-16. J HIV Ther. 2002. PMID: 12735215 Review. English, Spanish. No abstract available.
• Efavirenz: enhancing the gold standard.

  Arribas JR. Arribas JR. Int J STD AIDS. 2003 Oct;14 Suppl 1:6-14. doi: 10.1258/095646203322491824. Int J STD AIDS. 2003. PMID: 14617398 Review.